This study identified a wide range of compounds, including inhibitors of the PI3K/AKT/mTORC1 signaling pathway (i.e., idelalisib, everolimus, BKM-120), BCL2 family inhibitors (i.e., ABT-199) and other BCR pathway inhibitors that cooperate with ibrutinib to kill ABC-DLBCL cell lines [233]. Here, AKT1 is linked to diffuse large B-cell lymphoma.